ANXA8

Summary

ANXA8 (annexin A8, HGNC:546) is a protein-coding gene on chromosome 10q11.22, encoding Annexin A8 (P13928). This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.

This gene encodes a member of the annexin family of evolutionarily conserved Ca2+ and phospholipid binding proteins. The encoded protein may function as an an anticoagulant that indirectly inhibits the thromboplastin-specific complex. Overexpression of this gene has been associated with acute myelocytic leukemia. A highly similar duplicated copy of this gene is found in close proximity on the long arm of chromosome 10.

Source: NCBI Gene 653145 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 12 total
• Druggable target: yes
• MANE Select transcript: NM_001040084

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:546
Approved symbol	ANXA8
Name	annexin A8
Location	10q11.22
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000265190
Ensembl biotype	protein_coding
OMIM	602396
Entrez	653145

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000577813, ENST00000583448, ENST00000583874, ENST00000583911, ENST00000585281, ENST00000602274, ENST00000602877, ENST00000611843, ENST00000879794, ENST00000879795

RefSeq mRNA: 3 — MANE Select: NM_001040084 NM_001040084, NM_001271702, NM_001271703

CCDS: CCDS73121, CCDS73122, CCDS73123

Canonical transcript exons

ENST00000585281 — 12 exons

Exon	Start	End
ENSE00002686024	47467993	47468906
ENSE00002694955	47477081	47477194
ENSE00002708977	47476232	47476322
ENSE00002715803	47483913	47484115
ENSE00002719561	47475493	47475572
ENSE00003466356	47473970	47474065
ENSE00003478719	47478533	47478627
ENSE00003520572	47471262	47471384
ENSE00003529936	47474945	47475004
ENSE00003624586	47479798	47479888
ENSE00003678223	47474305	47474398
ENSE00003681099	47472133	47472191

Expression profiles

Bgee: expression breadth ubiquitous, 123 present calls, max score 98.40.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6086 / max 67.4512, expressed in 127 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
205850	0.4112	108
205849	0.1675	72
205851	0.0299	11

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	98.40	gold quality
lower esophagus mucosa	UBERON:0035834	98.37	gold quality
zone of skin	UBERON:0000014	97.74	gold quality
esophagus mucosa	UBERON:0002469	97.73	gold quality
skin of leg	UBERON:0001511	97.24	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.26	gold quality
placenta	UBERON:0001987	91.90	gold quality
vagina	UBERON:0000996	89.44	gold quality
omental fat pad	UBERON:0010414	86.80	gold quality
right lung	UBERON:0002167	85.72	gold quality
minor salivary gland	UBERON:0001830	84.48	gold quality
saliva-secreting gland	UBERON:0001044	83.14	gold quality
tonsil	UBERON:0002372	80.95	gold quality
upper lobe of left lung	UBERON:0008952	80.44	gold quality
urinary bladder	UBERON:0001255	78.41	gold quality
lung	UBERON:0002048	77.51	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.50	gold quality
esophagus	UBERON:0001043	76.18	gold quality
prostate gland	UBERON:0002367	75.39	gold quality
adipose tissue	UBERON:0001013	67.11	gold quality
left uterine tube	UBERON:0001303	66.18	gold quality
uterine cervix	UBERON:0000002	66.16	gold quality
ectocervix	UBERON:0012249	65.83	gold quality
fallopian tube	UBERON:0003889	65.38	gold quality
right lobe of liver	UBERON:0001114	65.01	gold quality
right atrium auricular region	UBERON:0006631	64.38	gold quality
thoracic mammary gland	UBERON:0005200	64.20	gold quality
right adrenal gland cortex	UBERON:0035827	62.87	gold quality
granulocyte	CL:0000094	62.60	gold quality
liver	UBERON:0002107	61.91	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-86618	yes	1129.63
E-CURD-114	yes	67.84
E-GEOD-130148	yes	11.73
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXO4, RARA

miRNA regulators (miRDB)

32 targeting ANXA8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-219A-1-3P	98.91	67.87	639
HSA-MIR-936	98.87	70.51	1124
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-4477A	98.83	69.75	2952
HSA-MIR-222-5P	98.75	69.17	1242
HSA-MIR-1178-3P	98.57	67.09	890
HSA-MIR-4662B	98.33	66.37	1163
HSA-MIR-4647	98.30	66.41	1139
HSA-MIR-3130-5P	98.14	66.00	711
HSA-MIR-3661	97.83	67.30	705
HSA-MIR-6728-5P	97.79	66.33	891
HSA-MIR-6787-3P	97.75	66.17	1233
HSA-MIR-631	97.05	66.93	602
HSA-MIR-3189-3P	96.80	66.34	896
HSA-MIR-342-3P	96.44	67.48	1344

Literature-anchored findings (GeneRIF, showing 15)

• Annexin A8 is involved in mouse mammary gland involution and progression of human breast cancer (PMID:16203777)
• binds Ca2+-dependently and with high specificity to phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) and is also capable of interacting with F-actin (PMID:16638567)
• Data suggest that defective transport through the late endocytic pathway and imbalanced signaling in the absence of annexin A8 results from disturbed association of late endosomal membranes with actin and impaired endosome motility. (PMID:18923148)
• Define a distinct bone-dependent genetic program associated with terminal osteoclast differentiation and identified Anxa8 as a gene strongly induced late in osteoclast differentiation, regulating formation of the cell’s characteristic actin ring. (PMID:21344395)
• High ANXA8 expression is associated with pancreatic cancer. (PMID:23001853)
• Annexin A8 controls leukocyte recruitment to activated endothelial cells via cell surface delivery of CD63. (PMID:24769558)
• Increased annexin A8 expression is associated with poor prognosis in early-stage pancreatic cancer. (PMID:25268673)
• High ANXA8 gene expression is associated with lymph node metastasis in oral squamous cell carcinoma. (PMID:26700817)
• Annexins A2 and A8 in endothelial cell exocytosis and the control of vascular homeostasis (PMID:27451994)
• We conclude that AnxA8 affects CD63/VEGFR2/beta1 integrin complex formation, leading to hyperactivation of the VEGF-A signal transduction pathway, and severely disturbed VEGF-A-driven angiogenic sprouting. (PMID:28060564)
• Data show that down-regulation of AnxA8 is both necessary and sufficient for neuronal trans-differentiation of retinal pigment epithelial (RPE) cells and reveal an essential role for AnxA8 as a key regulator of RPE phenotype. (PMID:28680125)
• These findings identify Anxa8 as a regulator of late endosomes/lysosomes cholesterol balance. (PMID:29306076)
• ANXA8 was significantly highly expressed in ovarian cancer, and high ANXA8 expression was significantly correlated with poor prognosis. (PMID:31474227)
• [ANXA8 Regulates Proliferation of Human Non-Small Lung Cancer Cells A549 via EGFR-AKT-mTOR Signaling Pathway]. (PMID:34671007)
• Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family. (PMID:37464398)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	anxa13l	ENSDARG00000013613
danio_rerio	anxa13	ENSDARG00000013976
danio_rerio	anxa14	ENSDARG00000100104
mus_musculus	Anxa8	ENSMUSG00000021950
rattus_norvegicus	Anxa8	ENSRNOG00000060949
drosophila_melanogaster	AnxB9	FBGN0000083
drosophila_melanogaster	AnxB11	FBGN0030749

Paralogs (12): ANXA13 (ENSG00000104537), ANXA10 (ENSG00000109511), ANXA11 (ENSG00000122359), ANXA1 (ENSG00000135046), ANXA7 (ENSG00000138279), ANXA3 (ENSG00000138772), ANXA9 (ENSG00000143412), ANXA5 (ENSG00000164111), ANXA2 (ENSG00000182718), ANXA4 (ENSG00000196975), ANXA6 (ENSG00000197043), ANXA8L1 (ENSG00000264230)

Protein

Protein identifiers

Annexin A8 — P13928 (reviewed: P13928)

Alternative names: Annexin VIII, Annexin-8, Vascular anticoagulant-beta

All UniProt accessions (4): A0A075B748, A0A075B765, A0A087WTN9, P13928

UniProt curated annotations — full annotation on UniProt →

Function. This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.

Domain organisation. A pair of annexin repeats may form one binding site for calcium and phospholipid.

Similarity. Belongs to the annexin family.

Isoforms (3)

UniProt ID	Names	Canonical?
P13928-1	1	yes
P13928-2	2
P13928-3	3

RefSeq proteins (3): NP_001035173, NP_001258631, NP_001258632 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001464	Annexin	Family
IPR009115	ANX8	Family
IPR018252	Annexin_repeat_CS	Conserved_site
IPR018502	Annexin_repeat	Repeat
IPR037104	Annexin_sf	Homologous_superfamily

Pfam: PF00191

UniProt features (45 total): helix 20, sequence conflict 5, strand 5, repeat 4, binding site 4, splice variant 3, sequence variant 2, chain 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
1W3W	X-RAY DIFFRACTION	1.99
1W45	X-RAY DIFFRACTION	2.51

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P13928-F1	94.23	0.90

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 266; 268; 270; 310

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 141 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, KOBAYASHI_EGFR_SIGNALING_24HR_UP, GOBP_ENDOSOME_ORGANIZATION, JAEGER_METASTASIS_DN, GOBP_VESICLE_ORGANIZATION, GCANCTGNY_MYOD_Q6, AP4_Q6, GOBP_VESICLE_MEDIATED_TRANSPORT, CAGCTG_AP4_Q5, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, GOBP_WOUND_HEALING, RICKMAN_METASTASIS_DN, AML_Q6, OCT1_06, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION

GO Biological Process (4): endosome organization (GO:0007032), blood coagulation (GO:0007596), endosomal transport (GO:0016197), hemostasis (GO:0007599)

GO Molecular Function (10): phosphatidylserine binding (GO:0001786), calcium ion binding (GO:0005509), calcium-dependent phospholipid binding (GO:0005544), phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), phosphatidylinositol-3,4,5-trisphosphate binding (GO:0005547), phospholipase A2 inhibitor activity (GO:0019834), phosphatidylinositol-3,4-bisphosphate binding (GO:0043325), actin filament binding (GO:0051015), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (7): cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), vesicle membrane (GO:0012506), extracellular matrix (GO:0031012), late endosome membrane (GO:0031902), sarcolemma (GO:0042383)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phospholipid binding	2
anion binding	2
phosphatidylinositol phosphate binding	2
phosphatidylinositol bisphosphate binding	2
cellular anatomical structure	2
endomembrane system organization	1
vesicle organization	1
hemostasis	1
wound healing	1
coagulation	1
vesicle-mediated transport	1
intracellular transport	1
regulation of body fluid levels	1
modified amino acid binding	1
metal ion binding	1
A2-type glycerophospholipase activity	1
phospholipase inhibitor activity	1
actin binding	1
protein-containing complex binding	1
binding	1
cation binding	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1
organelle membrane	1
vesicle	1
external encapsulating structure	1
late endosome	1
endosome membrane	1
plasma membrane	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

113 interactions, top by confidence:

A	B	Type	Score
ANXA8	ACTA1	psi-mi:“MI:0915”(physical association)	0.590
DR1	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
GTF2B	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	NEFL	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	PEX1	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	PMP22	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	PRPS1	psi-mi:“MI:0915”(physical association)	0.560
WFS1	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
DNALI1	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
BAG6	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
KLF11	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
GTF3C3	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
KIF1B	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
RNF11	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
COL26A1	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
SOD1	ANXA8	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	ATXN1	psi-mi:“MI:0915”(physical association)	0.560
ANXA8	TARDBP	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (72): ANXA8 (Affinity Capture-MS), ACTA1 (Affinity Capture-MS), ACTA1 (Affinity Capture-MS), ANXA8L1 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8L1 (Affinity Capture-RNA), ANXA8L1 (Proximity Label-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS), ANXA8 (Affinity Capture-MS)

ESM2 similar proteins: A2SW69, A5A6L7, A6NMY6, O35639, O35640, O97529, P04272, P07355, P07356, P08132, P08758, P09525, P12429, P13214, P13928, P14668, P14669, P14824, P14950, P17153, P17785, P19620, P22464, P24551, P24801, P26256, P27006, P27216, P48036, P50994, P51074, P55260, P70075, P81287, P93157, P97429, Q07936, Q29471, Q2Q1M6, Q3SWX7

Diamond homologs: A2SW69, A5A6L7, A5A6M2, A6NMY6, C0HJG9, C1L7Y4, C4QH88, O35639, O35640, O76027, O97529, P04083, P04272, P07150, P07355, P07356, P08132, P08133, P08758, P09525, P10107, P12429, P13214, P13928, P14087, P14668, P14669, P14824, P14950, P17153, P17785, P19619, P19620, P20072, P20073, P22464, P22465, P24551, P24639, P24801

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

12 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	3
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

2570 predictions. Top by Δscore:

Variant	Effect	Δscore
10:47474064:G:GG	acceptor_gain	1.0000
10:47474065:A:AG	acceptor_gain	1.0000
10:47475429:G:GT	donor_gain	1.0000
10:47475469:G:GT	donor_gain	1.0000
10:47476005:G:T	donor_gain	1.0000
10:47478539:T:G	donor_gain	1.0000
10:47478540:G:GG	donor_gain	1.0000
10:47478545:GC:G	donor_gain	1.0000
10:47483909:T:G	donor_loss	1.0000
10:47483910:G:GA	donor_loss	1.0000
10:47483911:GG:G	donor_gain	1.0000
10:47483911:GGT:G	donor_loss	1.0000
10:47483912:GG:G	donor_gain	1.0000
10:47483912:GGGT:G	donor_loss	1.0000
10:47483913:TGGG:T	donor_loss	1.0000
10:47468774:G:GT	donor_gain	0.9900
10:47472190:G:GG	acceptor_gain	0.9900
10:47472190:GT:G	acceptor_gain	0.9900
10:47472191:A:AG	acceptor_gain	0.9900
10:47474064:GT:G	acceptor_gain	0.9900
10:47474941:T:G	donor_loss	0.9900
10:47474942:G:GA	donor_loss	0.9900
10:47474944:AGGTG:A	donor_loss	0.9900
10:47474945:CAGG:C	donor_loss	0.9900
10:47474945:CAGGT:C	donor_loss	0.9900
10:47474946:ACAG:A	donor_loss	0.9900
10:47474946:ACAGG:A	donor_loss	0.9900
10:47475003:GGGCA:G	acceptor_gain	0.9900
10:47475453:G:GT	donor_gain	0.9900
10:47475457:TTTGG:T	donor_gain	0.9900

AlphaMissense

2187 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:47477097:A:G	L102P	0.997
10:47477089:C:G	A105P	0.995
10:47478573:C:G	R56P	0.995
10:47474394:A:G	L186P	0.993
10:47478551:G:C	F63L	0.993
10:47478551:G:T	F63L	0.993
10:47478553:A:G	F63L	0.993
10:47471301:G:C	F295L	0.992
10:47471301:G:T	F295L	0.992
10:47471303:A:G	F295L	0.992
10:47474017:A:T	I232N	0.992
10:47474313:A:G	L213P	0.992
10:47474950:C:G	A183P	0.992
10:47474349:A:G	F201S	0.991
10:47474386:C:G	A189P	0.991
10:47477107:C:G	A99P	0.991
10:47474017:A:C	I232S	0.990
10:47476276:C:G	R123P	0.990
10:47477106:G:T	A99D	0.990
10:47477178:A:G	L75S	0.990
10:47471337:C:A	R283S	0.989
10:47471337:C:G	R283S	0.989
10:47471344:A:T	V281D	0.989
10:47473985:C:G	A243P	0.989
10:47474348:G:C	F201L	0.989
10:47474348:G:T	F201L	0.989
10:47474350:A:G	F201L	0.989
10:47474394:A:T	L186Q	0.989
10:47475509:A:G	L159P	0.989
10:47477097:A:T	L102Q	0.989

dbSNP variants (sampled 300 via entrez): RS1009474 (10:47589556 G>A,C,T), RS10219043 (10:47896818 G>A), RS1028563248 (10:47988908 G>A,T), RS1045723 (10:47529706 C>A,T), RS10466322 (10:47901060 G>A), RS1046757 (10:47537607 T>C), RS1047435 (10:47502436 A>C,G,T), RS1047447 (10:47502343 T>C), RS1047466 (10:47502248 T>C,G), RS1047615 (10:47501918 A>G), RS1047621 (10:47501913 T>C,G), RS1047630 (10:47501906 T>C), RS1048157 (10:47922884 T>C), RS1048158 (10:47922935 T>C), RS1053559 (10:47731043 T>C,G)

Disease associations

OMIM: gene MIM:602396 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_287	Refractive error	2.000000e-49

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196069 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Smoke	decreases expression, increases abundance	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Air Pollutants	decreases expression, increases abundance	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	2
sulforaphane	decreases expression	1
cobaltous chloride	decreases expression	1
doxifluridine	decreases response to substance	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
isobutyl alcohol	increases abundance, increases expression, affects cotreatment	1
S 1 (combination)	decreases response to substance	1
chloropicrin	increases expression	1
bisphenol S	affects expression	1
(+)-JQ1 compound	decreases expression	1
Acetaminophen	decreases expression	1
Ethanol	increases expression, affects cotreatment, increases abundance	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Cytarabine	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Penicillin G	decreases expression	1
Phenobarbital	affects expression	1
Polycyclic Aromatic Hydrocarbons	increases expression, affects cotreatment, increases abundance	1
Tobacco Smoke Pollution	affects expression	1
Tretinoin	decreases expression	1
Triclosan	increases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	decreases expression, affects cotreatment	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6106833	Binding	Induction of ANXA8 degradation in human MDA-MB-231 cells at 0.5 to 6 uM incubated for 24 hrs by Western blot analysis relative to control	Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.